Massachusetts General Hospital: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 12 Leukemia, Lymphocytic, Chronic, B-Cell studies with Massachusetts General Hospital as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 2Phase 2 8No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingNCT06849713Phase 2
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• Ofatumumab for Initial Systemic Treatment of Indolent B-cell LymphomaCompletedNCT01239394Phase 2Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT00644189Phase 1/2Results posted
• Dasatinib in Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00438854Phase 2Results posted
• Biomarker for Infection Risk in CLL and MMActive, not recruitingNCT05844033
• Vaccine Responsiveness in Patients With Chronic Lymphocytic LeukemiaCompletedNCT05007860
• Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
• Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
• Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1